[en] In nuclear medicine, ^99mTc-MIBI is used for diagnoses of myocardinal perfusion, breast-cancer and whole body scan as well. Commercial MIBI dry kit, after being labelled with technetium-99m can cover 6 to 8 patients. However, in Indonesia nowadays, patients who need ^99mTc-MIBI is much lesser (2-3 patients/day) than the number mentioned above and due to the short half life (6 hours) of technetium-99m, so that the rest of the labelled compound can not be utilized. Concerning to the high cost of MIBI dry kit and the effort in achieving an optimum utilization of ^99mTc-MIBI, modification in formulating of MIBI dry kit has been carried out. Modification was done particularly in reducing the concentration of MIBI. Radiochemical purity was determined with thin layer chromatography using methanol and 0.9 % of NaCl as the solvents. Apparently formulation consist of 0.5 mg MIBI and 0.060 mg of SnCl₂.2H₂O as reducing agent still gave ±99% (99.12±0.35%) of radiochemical purity. Besides preparation of MIBI dry kit based on its formulation was carried out, so was done the determination of dry kit sterility using three kinds of media. The result shows that the kit was sterile. Stability test on ^99mTc-MIBI and MIBI dry kit was performed by determining their radiochemical purities after certain intervals of post labelling and post manufacturing. The results show that ^99mTc-MIBI radiopharmaceutical and MIBI dry kit were remained stable six hours after labelling (radiochemical purity : 98.90 ± 0.29%), and 5 months of storage at 4⁰C, respectively. Furthermore several toxicity tests done on mice show that the present product was not toxic. Clinical application of ^99mTc-MIBI with tomography technique using gamma camera shows that this radiopharmaceutical could be used for imaging either myocardial perfusion or breast cancer and whole body scan